This study aimed to evaluate the prognostic value of ELN2017 in predicting survival outcomes and to assess the impact of clinical and molecular factors such as age, FLT3 and NPM1 mutations, and allogeneic hematopoietic stem cell transplantation (allo‐HSCT).
Mobina Shrestha +4 more
wiley +1 more source
Derived numbers with respect to functions of bounded variation [PDF]
Ralph Jeffery
openalex +1 more source
Frailty Exacerbates Disability in Progressive Multiple Sclerosis
ABSTRACT Background To evaluate frailty in severe progressive multiple sclerosis (PMS) and to investigate the underlying mechanisms. Methods This prospective, cross‐sectional, multicenter study enrolled a late severe PMS group requiring skilled nursing (n = 53) and an age, sex, and disease duration‐matched control PMS group (n = 53).
Taylor R. Wicks +10 more
wiley +1 more source
Generalization bounds for a generator-regularized InfoGAN-inspired adversarial objective. [PDF]
Hasan M, Muia MN, Islam MM.
europepmc +1 more source
On the Hammerstein equation in the space of functions of bounded $\varphi $-variation in the plane [PDF]
Luis Azócar +3 more
openalex +1 more source
Real‐World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease
ABSTRACT Objective Satralizumab, a monoclonal antibody targeting the interleukin‐6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real‐world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
Li‐Tsung Lin +2 more
wiley +1 more source
Variational structures for the Fokker-Planck equation with general Dirichlet boundary conditions. [PDF]
Quattrocchi F.
europepmc +1 more source
An application of Jensen's inequality in determining the order of magnitude of multiple Fourier coefficients of functions of bounded φ-variation [PDF]
Bhikha Lila Ghodadra
openalex +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
IS<i>1216</i> drives the evolution of pRUM-like multidrug resistance plasmids in <i>Enterococcus faecium</i>. [PDF]
Allen F +3 more
europepmc +1 more source

